Safety information on medicines for healthcare professionals sent in February 2008

Printer friendly version (new window)

A list of letters sent to healthcare professionals in February 2008, to inform of new safety information and advice.

Date issued	Product	Safety information
01/02/2008	Nizoral (ketoconazole)	Restricted indications due to risk of hepatotoxicity (165Kb)
Week commencing 11/02/2008	Avelox (moxifloxacin)	Serious hepatic reactions and bullous skin reactions (33Kb)
11/02/2008	MabCampath (alemtuzumab)	Six infection-related deaths in clinical trial of fludarabine and rituximab treatement followed by alemtuzumab for remission consolidation in patients with previously untreated symptomatic B-cell chronic lymphocytic leukaemia (31Kb)
15/02/2008	Tazocin (piperacillin with tazobactam)	Reformulation (56Kb)
15/02/2008	Sebivo (telbivudine)	Risk of peripheral neuropathy (206Kb)
18/02/2008	CellCept (mycophenolate mofetil)	Reports of progressive multifocal leukoenecephalopathy (59Kb)
20/02/2008	Provigil (modafinil)	Serious skin rash and psychiatric symptoms (101Kb)

Page last modified: 07 April 2008

Find out about who we are and what we do. Also find out about working for us...

Find out how we regulate medicines (including herbal medicines), devices, tissue engineering, nanotechnology and blood...

Safety alerts, warnings, information and advice. Also how you can report a safety problem...

Information on our advisory committees including their meeting minutes and membership...

Details of our conferences, seminars and learning resources on topics related to our work...

Sign-up for e-mail notifications; report safety problems and links to other online services...

Details of our vast array of publications, many available to view online...

Breaking news and a full archive of our press releases. Also our press contacts and image library...

Give us your views on our consultations and our website. Also how you can make a complaint...